Apitoria Pharma Private Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is LAMIVUDINE USP, with a corresponding US DMF Number 18713.
Remarkably, this DMF maintains an Active status since its submission on August 18, 2005, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of February 22, 2017, and payment made on February 06, 2017, indicating their dedication to facilitating drug approvals, Categorized as Type II